EPO and chronic kidney disease: Roxadustat has been proven to induce RBC production while maintaining the plasma EPO levels within or near the normal physiologic range in multiple subpopulations of CKD patients (including in the presence of inflammation), without extra intravenous iron supplementation (Besarab et al., 2015; Besarab et al., 2016; Yan and Xu, 2020).